Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: Comparison with adult acute myeloid leukemia

Srdan Verstovsek, Taghi Manshouri, Franklin O. Smith, Francis J. Giles, Jorge Cortes, Elihu Estey, Hagop Kantarjian, Michael Keating, Sima Jeha, Maher Albitar

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Significantly elevated telomerase activity (TA) has been found in samples from patients with almost all malignant hematologic diseases. The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown. METHODS. Using a modified polymerase chain reaction-based, telomeric repeat-amplification protocol assay, the authors measured TA in bone marrow samples from 40 patients with P-AML and, for comparison, in 65 adult patients with AML (A-AML), excluding patients with French-American-British M3 disease. The results were correlated with patient characteristics and survival. RESULTS. TA in patients with P-AML was significantly lower compared with TA in patients with A-AML (P = 0.005). Patients who had P-AML with low TA had a projected 5-year survival rate of 88%, whereas patients who had P-AML with high TA had a projected 5-year survival rate of 43% (P = 0.009). Conversely, patients who had A-AML with very high TA (upper quartile) had significantly longer survival compared with patients who had A-AML with lower TA (P = 0.03). There was no correlation between complete remission rate or disease free survival and TA in P-AML or A-AML. In the A-AML group, when patients were separated by cytogenetic findings (poor prognosis vs. others), it was found that TA was significantly lower in patients with a poor prognosis, but the prognostic value of TA was not independent of cytogenetic status. CONCLUSIONS. The current results suggest, that for patients with P-AML, bone marrow TA is a highly significant prognostic factor.

Original languageEnglish (US)
Pages (from-to)2212-2217
Number of pages6
JournalCancer
Volume97
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Telomerase
Acute Myeloid Leukemia
Pediatrics
Cytogenetics
Survival Rate
Bone Marrow

Keywords

  • Adult acute myeloid leukemia
  • Pediatric acute myeloid leukemia (AML)
  • Prognosis
  • Telomerase activity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia : Comparison with adult acute myeloid leukemia. / Verstovsek, Srdan; Manshouri, Taghi; Smith, Franklin O.; Giles, Francis J.; Cortes, Jorge; Estey, Elihu; Kantarjian, Hagop; Keating, Michael; Jeha, Sima; Albitar, Maher.

In: Cancer, Vol. 97, No. 9, 01.05.2003, p. 2212-2217.

Research output: Contribution to journalArticle

Verstovsek, S, Manshouri, T, Smith, FO, Giles, FJ, Cortes, J, Estey, E, Kantarjian, H, Keating, M, Jeha, S & Albitar, M 2003, 'Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: Comparison with adult acute myeloid leukemia', Cancer, vol. 97, no. 9, pp. 2212-2217. https://doi.org/10.1002/cncr.11313
Verstovsek, Srdan ; Manshouri, Taghi ; Smith, Franklin O. ; Giles, Francis J. ; Cortes, Jorge ; Estey, Elihu ; Kantarjian, Hagop ; Keating, Michael ; Jeha, Sima ; Albitar, Maher. / Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia : Comparison with adult acute myeloid leukemia. In: Cancer. 2003 ; Vol. 97, No. 9. pp. 2212-2217.
@article{66da4382323b4a769e97cb6d902bd488,
title = "Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: Comparison with adult acute myeloid leukemia",
abstract = "BACKGROUND. Significantly elevated telomerase activity (TA) has been found in samples from patients with almost all malignant hematologic diseases. The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown. METHODS. Using a modified polymerase chain reaction-based, telomeric repeat-amplification protocol assay, the authors measured TA in bone marrow samples from 40 patients with P-AML and, for comparison, in 65 adult patients with AML (A-AML), excluding patients with French-American-British M3 disease. The results were correlated with patient characteristics and survival. RESULTS. TA in patients with P-AML was significantly lower compared with TA in patients with A-AML (P = 0.005). Patients who had P-AML with low TA had a projected 5-year survival rate of 88{\%}, whereas patients who had P-AML with high TA had a projected 5-year survival rate of 43{\%} (P = 0.009). Conversely, patients who had A-AML with very high TA (upper quartile) had significantly longer survival compared with patients who had A-AML with lower TA (P = 0.03). There was no correlation between complete remission rate or disease free survival and TA in P-AML or A-AML. In the A-AML group, when patients were separated by cytogenetic findings (poor prognosis vs. others), it was found that TA was significantly lower in patients with a poor prognosis, but the prognostic value of TA was not independent of cytogenetic status. CONCLUSIONS. The current results suggest, that for patients with P-AML, bone marrow TA is a highly significant prognostic factor.",
keywords = "Adult acute myeloid leukemia, Pediatric acute myeloid leukemia (AML), Prognosis, Telomerase activity",
author = "Srdan Verstovsek and Taghi Manshouri and Smith, {Franklin O.} and Giles, {Francis J.} and Jorge Cortes and Elihu Estey and Hagop Kantarjian and Michael Keating and Sima Jeha and Maher Albitar",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/cncr.11313",
language = "English (US)",
volume = "97",
pages = "2212--2217",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia

T2 - Comparison with adult acute myeloid leukemia

AU - Verstovsek, Srdan

AU - Manshouri, Taghi

AU - Smith, Franklin O.

AU - Giles, Francis J.

AU - Cortes, Jorge

AU - Estey, Elihu

AU - Kantarjian, Hagop

AU - Keating, Michael

AU - Jeha, Sima

AU - Albitar, Maher

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND. Significantly elevated telomerase activity (TA) has been found in samples from patients with almost all malignant hematologic diseases. The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown. METHODS. Using a modified polymerase chain reaction-based, telomeric repeat-amplification protocol assay, the authors measured TA in bone marrow samples from 40 patients with P-AML and, for comparison, in 65 adult patients with AML (A-AML), excluding patients with French-American-British M3 disease. The results were correlated with patient characteristics and survival. RESULTS. TA in patients with P-AML was significantly lower compared with TA in patients with A-AML (P = 0.005). Patients who had P-AML with low TA had a projected 5-year survival rate of 88%, whereas patients who had P-AML with high TA had a projected 5-year survival rate of 43% (P = 0.009). Conversely, patients who had A-AML with very high TA (upper quartile) had significantly longer survival compared with patients who had A-AML with lower TA (P = 0.03). There was no correlation between complete remission rate or disease free survival and TA in P-AML or A-AML. In the A-AML group, when patients were separated by cytogenetic findings (poor prognosis vs. others), it was found that TA was significantly lower in patients with a poor prognosis, but the prognostic value of TA was not independent of cytogenetic status. CONCLUSIONS. The current results suggest, that for patients with P-AML, bone marrow TA is a highly significant prognostic factor.

AB - BACKGROUND. Significantly elevated telomerase activity (TA) has been found in samples from patients with almost all malignant hematologic diseases. The impact of elevated TA on the course of pediatric patients with acute myeloid leukemia (P-AML) is unknown. METHODS. Using a modified polymerase chain reaction-based, telomeric repeat-amplification protocol assay, the authors measured TA in bone marrow samples from 40 patients with P-AML and, for comparison, in 65 adult patients with AML (A-AML), excluding patients with French-American-British M3 disease. The results were correlated with patient characteristics and survival. RESULTS. TA in patients with P-AML was significantly lower compared with TA in patients with A-AML (P = 0.005). Patients who had P-AML with low TA had a projected 5-year survival rate of 88%, whereas patients who had P-AML with high TA had a projected 5-year survival rate of 43% (P = 0.009). Conversely, patients who had A-AML with very high TA (upper quartile) had significantly longer survival compared with patients who had A-AML with lower TA (P = 0.03). There was no correlation between complete remission rate or disease free survival and TA in P-AML or A-AML. In the A-AML group, when patients were separated by cytogenetic findings (poor prognosis vs. others), it was found that TA was significantly lower in patients with a poor prognosis, but the prognostic value of TA was not independent of cytogenetic status. CONCLUSIONS. The current results suggest, that for patients with P-AML, bone marrow TA is a highly significant prognostic factor.

KW - Adult acute myeloid leukemia

KW - Pediatric acute myeloid leukemia (AML)

KW - Prognosis

KW - Telomerase activity

UR - http://www.scopus.com/inward/record.url?scp=0345381983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345381983&partnerID=8YFLogxK

U2 - 10.1002/cncr.11313

DO - 10.1002/cncr.11313

M3 - Article

C2 - 12712473

AN - SCOPUS:0345381983

VL - 97

SP - 2212

EP - 2217

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -